Forian Inc. (Nasdaq: FORA), a provider of data analytics and information solutions for healthcare and life sciences, announced the completion of its acquisition by an affiliate of 2025 Acquisition Company, LLC. The transaction, finalized on May 15, 2026, includes a cash tender offer and subsequent merger, taking the company private. Forian's common stock will be delisted from the Nasdaq Stock Market, ending its public trading.
The acquisition was executed through a cash tender offer by Bravo Merger Sub, Inc., a wholly owned subsidiary of 2025 Acquisition Company, LLC (Parent). The offer, which expired on May 14, 2026, allowed shareholders to tender their shares at $2.17 per share in cash, without interest. According to the depositary, Broadridge Corporate Issuer Solutions, LLC, 6,444,415 shares were validly tendered and not withdrawn. Combined with the 21,887,631 shares already owned by the Buyer Parties—representing approximately 70% of outstanding shares—the minimum condition for the offer was satisfied. Following the acceptance of tendered shares, Merger Sub merged with and into Forian, with Forian surviving as a wholly owned subsidiary of Parent.
Under the terms of the merger agreement, dated April 2, 2026, each outstanding share of Forian common stock not owned by the Buyer Parties or their subsidiaries was converted into the right to receive $2.17 per share in cash, the same consideration as the tender offer. The merger was effected under Section 3-106.1 of the Maryland General Corporation Law without a stockholder vote.
As a result, Forian's common stock will cease trading on Nasdaq before market open on May 15, 2026. The company has requested that Nasdaq file a Form 25 with the U.S. Securities and Exchange Commission (SEC) to effect the delisting. Additionally, Forian intends to file a Form 15 with the SEC to terminate the registration of its common stock under the Securities Exchange Act of 1934 and suspend its reporting obligations.
Forian provides data management and analytics solutions to optimize operational, clinical, and financial performance for clients in life sciences, healthcare, and financial services. The company specializes in acquiring and normalizing large-scale healthcare data, overlaying data science capabilities on a clinical data lake to generate proprietary insights. More information is available on the company's website at www.forian.com.
This move to go private may offer Forian greater flexibility in executing long-term strategies without the pressures of quarterly earnings reporting and public market scrutiny. For industry observers, the acquisition highlights ongoing consolidation in the healthcare data analytics sector, as investors seek to capitalize on the growing demand for data-driven decision-making in healthcare. Leaders in business and technology should note the implications for data privacy and competition, as private ownership could accelerate Forian's development of proprietary analytics tools.
The transaction underscores the value of specialized data assets in healthcare, a sector increasingly reliant on analytics to improve outcomes and reduce costs. As Forian integrates into its new parent company, its customers and partners may see shifts in product offerings or service models.
